China Pharmaceutical Industry Association (CPIA) You have a very long history in the Chinese pharmaceutical industry, first in the joint venture company Xian-Janssen and then in the China National Pharmaceutical Group. Could you highlight the main evolutions of the Chinese pharmaceutical industry through these fast-changing times? It is indeed true that we have undergone tremendous…
China MSD China’s Michel Vounastos gives his initial impressions of the opportunities and challenges inherent in the Chinese healthcare market, and highlights how MSD’s offerings are able to address specific gaps in the country. You just arrived in China in February. The country managers we’ve met have all been here for…
Novartis Chile Novartis’ pharmaceutical activities include innovators, generics and biopharmaceuticals. How has your portfolio developed in Chile? What therapeutic areas is Novartis favoring in the Chilean context? Novartis is one of the Top 5 pharmaceutical companies at an international level. We have products in all the therapeutic areas inside the ethical pharmaceutical…
Merck Sharp & Dohme Chile What have been MSD’s major milestones and achievements since your establishment in Chile in 1995? We have recently gone through a global merger with Schering Plough, which occurred exactly a year ago. With this in mind, the first milestone that I can mention is the integration of these two relatively…
Janssen-Cilag Chile Janssen-Cilag has been investing heavily in its Latin American operations in the past years. What is the relative importance of the Chilean operations for Janssen-Cilag in Latin America and what are the major milestones and achievements since the company’s establishment in Chile? In the last five years we have been…
Novo Nordisk China We found a Capital Markets Day presentation from Novo Nordisk that talked about the “rule of halves” – that of all people with diabetes, 50% of diagnosed, and of those 50% have access to care, and of those 50% get decent care, and finally 50% of those reach their targets.…
Medicilon/MPI Preclinical Research Shanghai You completed your higher education in the US and worked there for a period afterwards; what caused you to move back to China and start this company? A lot of people are now returning to China after gaining extensive experience in the US. I personally enjoyed the vast experience that…
HUYA Bioscience International - China Your business is very much relationship based here in China. You’ve now established a number of relationships with institutes, universities and companies, but I can imagine that breaking into this market and building those relationships was a challenge. How did you grow this business in the early days? The early…
COFEPRIS It’s been one year since you were appointed as Federal Commissioner of COFEPRIS in March 2011. What have been the biggest challenges you’ve faced within this time? The biggest challenge was to familiarize myself with the new agency, which has very wide powers as it regulates many industries. COFEPRIS regulates…
MSD Brasil When we were in Australia, we met with the “star scientist” Ian Frazier, who was Australian of the Year in 2009 for his co-discovery of Merck’s Gardasil. Or Singulair, which is the trade name of Montelukast, with the Mont signifying “Montreal” where the product was developed. What will it take…
Brazil In an exclusive interview, Otto Philipp Braun, part of medtech giant B. Braun’s family dynasty, discusses his achievements as MD in Brazil, the company’s operations in the country and globally, as well as its CSR programs. B. Braun has been established in Brazil for more than 40 years, with its headquarters…
A.G. (CIF) What was the vision behind the creation of the Camara de la Industria Farmaceutica de Chile (CIF) and what have been the main milestones and achievements? CIF was created in 1953 and was originally composed of all the pharmaceutical laboratories operating in the country. Today CIF is a chamber that…
See our Cookie Privacy Policy Here